Observational studyNeuroradiology2025
Real-World outcomes of thrombectomy for distal medium vessel occlusions in the middle East and North Africa region: A multicenter registry analysis.
Observational study in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MeVO: To Treat or Not To Treat? Review of the Latest Evidence.Current neurology and neuroscience reports · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecent randomized trials showed neutral results for distal medium vessel occlusion (DMVO) thrombectomy, but real-world effectiveness across diverse healthcare settings remains unknown. We evaluated DMVO thrombectomy outcomes in the Middle East and North Africa (MENA) region.
methodsThe MEMENTO registry retrospectively analyzed consecutive DMVO thrombectomy patients (M2, M3, A2-3, P2-3 segments) across 15 centers (2022-2024). DMVOs were classified as primary, baseline secondary, or iatrogenic secondary. Primary outcome was 90-day functional independence (mRS 0-2). Secondary outcomes included successful recanalization (TICI ≥ 2b), mortality, and symptomatic hemorrhage.
resultsAmong 164 patients (median age 72, NIHSS 10), subtypes included primary (25%), baseline secondary (50%), and iatrogenic secondary (25%) DMVOs. Overall successful recanalization was 69%, with primary DMVOs achieving higher rates than baseline secondary (78% vs. 59%, p = 0.046). Good functional outcome occurred in 54% overall, with no significant differences between subtypes (primary 59%, baseline secondary 51%, iatrogenic secondary 54%, p = 0.661). Stent retriever achieved highest recanalization (85%) followed by combination (74%) and aspiration (45%, p = 0.046). Independent predictors of poor outcome included age > 75 (aOR 2.34, 95% CI 1.18-4.64), NIHSS > 15 (aOR 3.12, 95% CI 1.45-6.71), and unsuccessful recanalization (aOR 4.89, 95% CI 2.31-10.35). Cost-effectiveness analysis across MENA income levels yielded ICERs of $26,875-$71,333/QALY, exceeding regional GDP thresholds. The modest numerical difference in outcomes (54% vs. 45% historical controls) does not establish clinical benefit given neutral randomized trial results.
conclusionsReal-world DMVO thrombectomy outcomes closely mirror recent randomized trial results showing limited clinical benefit compared to medical management across diverse healthcare settings, with prohibitive economic costs that challenge routine implementation. These findings support highly selective application focusing on younger patients with moderate deficits and primary occlusions.
Indexed as
Identifiers
41137925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.